Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The latest update is out from Arbutus Biopharma ( (ABUS) ).
On April 15, 2026, Arbutus Biopharma announced that the U.S. Food and Drug Administration granted Fast Track designation to imdusiran for the treatment of chronic hepatitis B, a serious liver infection with significant unmet medical need affecting hundreds of millions globally. The designation, which follows Phase 2a data showing functional cures in some patients and sustained treatment-free control in others with a favorable safety profile, is expected to streamline development and regulatory interactions, potentially accelerating imdusiran’s path toward market and reinforcing Arbutus’s position in the competitive hepatitis B therapeutics landscape.
Chronic hepatitis B remains a major global health burden despite existing vaccines and therapies, with high rates of cirrhosis, liver cancer, and mortality. The Fast Track status for imdusiran highlights regulatory recognition of the therapy’s promise and may enhance Arbutus’s strategic standing among investors, partners, and rivals pursuing curative treatments for hepatitis B.
The most recent analyst rating on (ABUS) stock is a Buy with a $7.00 price target. To see the full list of analyst forecasts on Arbutus Biopharma stock, see the ABUS Stock Forecast page.
Spark’s Take on ABUS Stock
According to Spark, TipRanks’ AI Analyst, ABUS is a Neutral.
The score is held down primarily by weak financial performance (ongoing losses and cash burn) and soft technical momentum. A major offset is the transformative Moderna settlement, which improves the outlook for funding and potential shareholder returns, while valuation support is limited due to negative earnings and no dividend data.
To see Spark’s full report on ABUS stock, click here.
More about Arbutus Biopharma
Arbutus Biopharma Corporation is a clinical-stage biopharmaceutical company focused on infectious diseases, particularly chronic hepatitis B. The company is developing imdusiran (AB-729), an RNA interference therapeutic targeting hepatitis B viral proteins, and an oral PD-L1 inhibitor (AB-101), while also supporting intellectual property enforcement related to its lipid nanoparticle technology.
Average Trading Volume: 2,304,163
Technical Sentiment Signal: Buy
Current Market Cap: $854.2M
For a thorough assessment of ABUS stock, go to TipRanks’ Stock Analysis page.